Mary Jo Laffler
Latest From Mary Jo Laffler
Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
Pandemic Perspectives: R&D Lessons Learned From The COVID Year
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.
Predicting Success: The Easiest, And Hardest Routes To Market
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
BI Finds Right Fit For Digital Therapeutic Partnership With Click
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.